Swiss National Bank Decreases Holdings in Thermo Fisher Scientific Inc. $TMO

Swiss National Bank decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,034,800 shares of the medical research company’s stock after selling 53,400 shares during the quarter. Swiss National Bank’s holdings in Thermo Fisher Scientific were worth $599,615,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of TMO. High Note Wealth LLC lifted its stake in Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. Beacon Financial Strategies CORP purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Core Wealth Advisors LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $30,000. Finally, HFM Investment Advisors LLC lifted its stake in Thermo Fisher Scientific by 341.7% in the 4th quarter. HFM Investment Advisors LLC now owns 53 shares of the medical research company’s stock valued at $31,000 after buying an additional 41 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company reduced their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Barclays reduced their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Jefferies Financial Group raised Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price target for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Finally, KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $608.95.

Thermo Fisher Scientific Trading Down 1.4%

Shares of TMO opened at $475.12 on Friday. The stock has a fifty day moving average of $479.68 and a two-hundred day moving average of $528.09. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The company has a market capitalization of $176.56 billion, a PE ratio of 26.12, a price-to-earnings-growth ratio of 2.13 and a beta of 0.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating the consensus estimate of $5.25 by $0.19. The company had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.Thermo Fisher Scientific’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This represents a 1.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.